Carson Kessler

Oct 23, 2024 | spokesman.com | Walt Bogdanich |Carson Kessler

By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401. For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the drug’s effectiveness and safety, Eisai sought to include people whose genetic profiles made them especially prone to develop Alzheimer’s.

Oct 7, 2024 | pressdemocrat.com | Megan Twohey |Danielle Ivory |Carson Kessler

Deborah Hasin, a professor of epidemiology at Columbia University in New York, analyzed data from the federal government's annual National Survey on Drug Use and Health to calculate rates of cannabis use disorder among self-identified cannabis users. Rates were determined for various age groups and for different types of users - those who had consumed cannabis at all in the previous year, and those who had consumed it almost daily.